Latest news with #TSXVenture50™
Yahoo
23-05-2025
- Business
- Yahoo
Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 23, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ('Nova Leap' or 'the Company') announced today that its shareholders voted in favour of all items of business brought before them at the Company's annual and special meeting of shareholders held on May 23, 2025. At the meeting, the six nominees to the Company's Board of Directors ('the Board'), Chris Dobbin, Dana Hatfield, Michael O'Keefe, Wayne Myles, Marie Mullally and Anne Whelan, were elected for the ensuing year. Doane Grant Thornton LLP was re-appointed as the Company's auditor to hold office until the next annual meeting of shareholders or until its successor is duly appointed, at a remuneration to be fixed by the Board. In addition, the 10% 'rolling' third amended and restated equity incentive plan of the Company (the 'Plan') was approved and ratified. More information on the Plan is available in the Company's Management Information Circular dated April 24, 2025 filed on SEDAR+. The proxy results for the annual and special meeting of the shareholders held on May 23, 2025 were as follows:TOTAL SHAREHOLDERS VOTED BY PROXY: 51 TOTAL SHARES ISSUED & OUTSTANDING: 87,314,252 TOTAL SHARES VOTED: 38,917,906 TOTAL % OF SHARES VOTED: 44.57% About Nova Leap Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #42 ranking on the 2021 Report on Business ranking of Canada's Top Growing Companies, the #2 ranking on the 2020 Report on Business ranking of Canada's Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in the New England, Southeastern, South Central and Midwest regions of the United States as well as in Nova Scotia, Canada. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. A photo accompanying this announcement is available at CONTACT: For further information: Chris Dobbin, CPA, ICD.D Director, President and CEO E: cdobbin@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
10-03-2025
- Business
- Associated Press
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - March 10, 2025) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company') is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange ('TSXV'). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone's leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone's strong market performance and strategic advances in the past year including 110% share price appreciation and 209% market cap growth. The TSX Venture 50™ recognizes the top 50 performing issuers out of the 1,605 i listed issuers on the TSXV, across all sectors. Each company recognized is evaluated and chosen based on a combination of metrics including one year share price appreciation and market capitalization growth. In 2024, the 50 selected companies delivered an impressive average share price appreciation of 207% ii demonstrating strong investor confidence in high-growth enterprises. 'We are deeply honored to be recognized as a TSX Venture 50™ company. This reflects our unwavering commitment to advancing exosome-based therapies and creating long-term value for our shareholders,' said Dr. Lior Shaltiel, CEO of NurExone. 'It's a testament to the growing investor confidence in our mission to revolutionize regenerative medicine, the strength of our scientific breakthroughs, and the dedication of our talented team.' Key milestones driving NurExone's success include significant progress in the development of ExoPTEN, the Company's proprietary exosome therapy for acute spinal cord injuries, as well as NurExone's establishment of its U.S. subsidiary, Exo-Top Inc., which accelerates its exosome production capabilities and advancement of their clinical pipeline. These efforts will help position NurExone as a leader in the rapidly growing field of exosome-based therapies. The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated internationally across Europe, South America, Africa, and beyond iii, further highlighting the global impact of TSXV-listed firms. Yoram Drucker, Chairman of NurExone, added 'being recognized by the TSX Venture 50™ is a significant milestone for NurExone, highlighting our strong financial performance and growth trajectory. We look forward to continuing our success as we expand our presence in the U.S. and explore new listing opportunities.' About NurExone NurExone Biologic Inc. is a TSXV, OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets [iv]. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: [email protected] Oak Hill Financial Inc. 2 Bloor Street, Suite 2900 Toronto, Ontario M4W 3E2 Investor Relations - Canada Phone: +1-647-479-5803 Email: [email protected] Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Allele Capital Partners Investor Relations - U.S. Phone: +1 978-857-5075 FORWARD-LOOKING STATEMENTS This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company's advancing exosome-based therapies and creating long term value for shareholders; growing investor confidence in the Company's mission; Exo-Top Inc. accelerating its exosome production capabilities and advancing its clinical pipeline; the Company becoming a leader in the field of exosome-based therapies; the continued success of the Company; the Company expanding its presence in the U.S. and exploring new listing opportunities; the Company completing clinical trials in the U.S. and Europe; the Company's future plans and expectations; growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone advancing its development pipeline; NurExone's focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology offering solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will advance exosome-based therapies and create long term value for shareholders; there being growing investor confidence in the Company's mission; Exo-Top Inc. will accelerate its exosome production capabilities and advance its clinical pipeline; the Company will become a leader in the field of exosome-based therapies; the Company will continue to succeed; the Company will expand its presence in the U.S. and explore new listing opportunities; the Company will complete clinical trials in the U.S. and Europe; there will be growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone will advance its development pipeline; NurExone will continue to focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology will offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, and on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; the Company's inability to expand into further studies; Exo-Top not have the intended benefits on the Company and/or its business; the Company be unable to advance exosome-based therapies and/or create long term value for shareholders; investor confidence in the Company's mission deteriorating; the Company not becoming a leader in the field of exosome-based therapies; the Company being unable to expand its presence in the U.S. and/or explore new listing opportunities; the Company being unable to initiate and/or complete clinical trials in the U.S. and Europe; clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas deteriorating; NurExone being unable to advance its development pipeline; NurExone being unable to focus on developing regenerative exosome-based therapies for central nervous system injuries; the NurExone platform technology being unable to offer solutions to companies interested in quality exosomes and/or minimally invasive targeted delivery systems for other indications; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's annual information form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Associated Press
19-02-2025
- Business
- Associated Press
Newcore Gold Recognized as a 2025 TSX Venture 50 Company
VANCOUVER, British Columbia, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Newcore Gold Ltd. ('Newcore' or the 'Company') (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce that the Company has been recognized as one of the top 50 performing companies for 2024 on the TSX Venture Exchange ('TSXV'). The TSX Venture 50™ is an annual ranking of the top fifty performing companies from the past year on TSXV, out of over 1,600 TSXV issuers. The ranking is an equal weighting of each company's performance during 2024 across three criteria: market capitalization growth, share price appreciation and Canadian consolidated trading value. Luke Alexander, President and CEO of Newcore stated, 'We are very proud to have been recognized as a top performer on the TSXV in 2024. Our inclusion on the list recognizes our team's efforts to date and our strong share price appreciation of 121% in 2024. As we continue to advance our district scale Enchi Gold Project in Ghana we remain focused on continuing to build value for all our shareholders and stakeholders.' For further details on the 2025 TSX Venture 50™ visit: About Newcore Gold Ltd. Newcore Gold is advancing its Enchi Gold Project located in Ghana, Africa's largest gold producer (1). Newcore Gold offers investors a unique combination of top-tier leadership, who are aligned with shareholders through their 18% equity ownership, and prime district scale exploration opportunities. Enchi's 248 km2 land package covers 40 kilometres of Ghana's prolific Bibiani Shear Zone, a gold belt which hosts several multi-million-ounce gold deposits, including the Chirano mine 50 kilometres to the north. Newcore's vision is to build a responsive, creative and powerful gold enterprise that maximizes returns for shareholders. (1) Source: Production volumes for 2023 as sourced from the World Gold Council. On Behalf of the Board of Directors of Newcore Gold Ltd. Luke Alexander President, CEO & Director For further information, please contact: Mal Karwowska | Vice President, Corporate Development and Investor Relations +1 604 484 4399 [email protected] Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release includes statements that contain 'forward-looking information' within the meaning of the applicable Canadian securities legislation ('forward-looking statements'). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: statements about the estimation of mineral resources; results of preliminary economic assessments; completion of a pre-feasibility study; results of metallurgical testwork; results of our ongoing drill campaign; results of drilling, magnitude or quality of mineral deposits; anticipated advancement of mineral properties or programs; and future exploration prospects. These forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business. The assumptions underlying the forward-looking statements are based on information currently available to Newcore. Although the forward-looking statements contained in this news release are based upon what management of Newcore believes, or believed at the time, to be reasonable assumptions, Newcore cannot assure its shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Forward-looking information also involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others: risks related to the speculative nature of Newcore's business; Newcore's formative stage of development; Newcore's financial position; possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold and other commodities; fluctuations in currency markets (such as the Canadian dollar to United States dollar exchange rate); change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, unusual or unexpected geological formations); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties. Forward-looking statements contained herein are made as of the date of this news release and Newcore disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.
